[1] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[2] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[3] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[4] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[5] |
WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili.
Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
|
[6] |
HAO Gang, HAN Feng, ZHOU Gang, WU Xing, YAN Hao, LI Xuyang, HOU Hailing, NING Xiao, CUI Li.
Methodological study of adenosylcobalamin bacterial endotoxin examination for injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1351-1356.
|
[7] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[8] |
ZHONG Lumiao, DU Juan, DENG Hua, WANG Yafeng, QIU Ping, ZENG Linggui.
Thoughts on design and quality management of active safety surveillance research of traditional Chinese medicine injections initiated by Marketing Authorization Holder
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 994-998.
|
[9] |
HUANG Ying, HOU Tiantian, QIN Chao, HUO Yan, WANG Sanlong, WEN Hairuo, GENG Xingchao.
Nonclinical research on CAR-T cell products: main concerns and key issues
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 813-816.
|
[10] |
HUANG Ying, WEN Hairuo, HOU Tiantian, HUO Yan, WANG Sanlong, GENG Xingchao.
Cloning ability of CAR-T cells in soft agar and tumorigenicity in vitro
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 836-838.
|
[11] |
FU Lu, PENG Huasheng, YUAN Yuan, JIN Yan.
Herbal textual research on toxicity of Zanthoxylum bungeanum
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 369-371.
|
[12] |
YANG Jingfan, XU Lu, CHEN Suiqing.
Textual research of the toxic herb Kansui Radix
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 372-375.
|
[13] |
CUI Can, WEI Hongtao, CHENG Sheng, SHEN Su.
Adverse reactions induced by teriparatide
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 333-335.
|
[14] |
LIU Min, PEI Xiaojing, WANG Haixue.
Problems with and suggestions about expedited reporting of suspected unexpected serious adverse reactions during clinical trials of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 176-179.
|
[15] |
WU Chen, LIU Cuili, WANG Tao.
Cardiovascular safety of haloperidol preparations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.
|